Colossal Biosciences

About The Fund

Colossal Biosciences is a pioneering firm at the intersection of advanced genetic science and biodiversity conservation. With a primary focus on de-extinction, their mission is to combat the problem of extinction by leveraging gene editing and other scientific technologies. They are committed to reviving extinct species such as the woolly mammoth, thylacine, and dodo - creatures that once had a significant impact on ecosystems. Their work involves collecting viable DNA samples and editing genes to bring about the resurgence of these megafaunas in their natural habitats. Led by CEO Ben Lamm, Colossal includes influential figures like the geneticist George Church, and is supported by a comprehensive scientific advisory board with experts across scientific disciplines. The goal is not only to reintroduce these species but also to drive forward innovations in genetics that can have widespread benefits for environmental recovery and human well-being. Beyond de-extinction, Colossal contributes to conservation efforts more broadly and aims to incite global change for a healthier, more biodiverse planet. They work alongside conservation partners to protect endangered species and engage in rewilding initiatives to repair and restore natural environments. With an investment scope in Software, Media, BioTech, Blockchain, Gaming, Advertising, and LegalTech, they provide financial backing predominantly in early stages like Seed and Series A, with a sweet spot of $1,500,000, and they operate within a range of $100,000 to $5,000,000. Their unique blend of scientific innovation and entrepreneurial spirit makes them a significant player in the biosciences industry and a catalyst for eco-positive transformations.